GENENTECH, INC.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 496
- Registration Number
- NCT02983227
- Locations
- πΊπ¦
CNI Consultative and Diagnostic Center of Desnianskyi District of Kyiv, Kyiv, Ukraine
π΅π±Centrum Medyczne Pratia Katowice I, Katowice, Poland
π΅π±CCBR - Lodz - PL, Lodz, Poland
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
- Conditions
- Interventions
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT02927301
- Locations
- πΊπΈ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈUCLA Cancer Center, Santa Monica, California, United States
πΊπΈUniversity Of Colorado, Aurora, Colorado, United States
A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT02908100
- Locations
- πΊπΈ
Institute of Arthritis Research, Idaho Falls, Idaho, United States
πΊπΈValerius Medical Group & Research Ctr of Greater Long Beach, Los Alamitos, California, United States
πΊπΈRASF-Clinical Research Center, Boca Raton, Florida, United States
A Study to Assess the Relative Bioavailability And Food Effect of a Tablet Formulation of GDC-0276 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02856152
- Locations
- π¬π§
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT02848651
- Locations
- πΊπΈ
Franciscan St. Francis Health; Research Services, Indianapolis, Indiana, United States
πΊπΈVirginia Piper Cancer Inst, Minneapolis, Minnesota, United States
πΊπΈLevine Cancer Institute-Carolinas Medical Center; Levine Cancer Institute-Carolinas Medical Center, Charlotte, North Carolina, United States
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
- Conditions
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 578
- Registration Number
- NCT02833350
- Locations
- πΊπΈ
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
πΊπΈMedvin Clinical Research, Covina, California, United States
πΊπΈTriWest Research Associates, LLC, El Cajon, California, United States
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02833389
- Locations
- πͺπΈ
Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
πΊπΈClinical Research Associates Of Central Pa , Llc, Altoona, Pennsylvania, United States
πͺπΈUniversidad Complutense de Madrid, Madrid, Spain
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT02820896
- Locations
- πΊπΈ
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
- Conditions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02807285
- Locations
- πΊπΈ
University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈSteward St. Elizabeth's Medical Center, Boston, Massachusetts, United States
πΊπΈUniversity Of Texas Health Science Center Houston, Houston, Texas, United States
A Pharmacokinetic Study of [14C]-GDC-0810 After Single Oral Administration in Healthy Female Participants
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02802670